Avestria Ventures

Avestria Ventures is a California-based venture capital firm founded in 2018 by veteran life science executives Linda Greub and Corinne Nevinny. Operating from the San Francisco Bay Area and Beverly Hills, the firm invests in early-stage women's health and life science companies, with a primary focus on women-led founding teams — a market segment that has historically been underfunded relative to its commercial and clinical potential. Avestria leads rounds with typical checks of $500,000 to $5 million across pre-seed through Series A stages. The firm has made 43 investments and achieved notable portfolio exits, including Alydia Health's acquisition by Organon for up to $240 million and Uqora's acquisition by Pharmavite. Avestria closed Fund I in 2021 and has continued deploying through Fund II. With a team of 20 including 6 partners, the firm brings deep life sciences industry expertise across regulatory, clinical, and commercial pathways that matter most for health companies navigating product development to market. Avestria is one of the few dedicated venture funds at the intersection of women's health innovation and female-founded companies — a dual focus that reflects both a market conviction and an investment philosophy. The firm's large advisory network provides portfolio companies with the domain-specific guidance needed to navigate FDA processes, clinical trial design, and pharma partnership negotiations. Greub and Nevinny's combined decades of life science industry experience give Avestria a credibility advantage with founders, corporates, and co-investors that sector-agnostic funds cannot easily replicate.